Johnson & Johnson Stock Buenos Aires S.E.

Equities

JNJ

ARDEUT110236

Pharmaceuticals

End-of-day quote Buenos Aires S.E. 06:00:00 2024-06-18 pm EDT 5-day change 1st Jan Change
12,579 ARS +2.26% Intraday chart for Johnson & Johnson -0.39% +24.12%
Sales 2024 * 88.79B 80,416B Sales 2025 * 92.1B 83,423B Capitalization 351B 317,492B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.95 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.81 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 131,900
Yield 2024 *
3.31%
Yield 2025 *
3.46%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.26%
1 week-0.39%
Current month+3.04%
1 month+10.48%
3 months+11.64%
6 months+27.29%
Current year+24.12%
More quotes
1 week
12 100.00
Extreme 12100
12 729.50
1 month
11 444.50
Extreme 11444.5
13 490.00
Current year
9 977.00
Extreme 9977
14 499.00
1 year
5 404.00
Extreme 5404
14 499.00
3 years
1 816.67
Extreme 1816.6667
14 499.00
5 years
361.17
Extreme 361.1667
14 499.00
10 years
68.15
Extreme 68.15
14 499.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-06-19 12,579 +2.26% 2,038
24-06-18 12,300 -0.13% 4,560
24-06-14 12,317 -0.17% 4,871
24-06-13 12,338 -2.30% 13,713
24-06-12 12,628 -1.38% 22,138

End-of-day quote Buenos Aires S.E., June 18, 2024

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
145.6 USD
Average target price
171.7 USD
Spread / Average Target
+17.90%
Consensus